Background & Plunge Catalyst
XOMA Corporation (NASDAQ: XOMA) is a biotech royalty aggregator – instead of developing drugs, it acquires rights to future milestone payments and royalties on drug candidates developed by other companies ([1]) ([2]). This unique model gives XOMA a portfolio of over 120 partnered assets, including several drugs in late-stage trials and a handful of recently approved products generating royalty income ([3]) ([4]). However, this strategy also means XOMA’s fortunes are tied to the success of its partners’ drug programs. That risk became reality on December 11, 2025, when one of XOMA’s key royalty assets suffered a major setback. XOMA’s stock plummeted over 20% in one day, as a partner company Rezolute announced that its Phase 3 trial for the drug RZ358 (ersodetug) failed to meet its primary endpoint ([5]). Rezolute’s study in congenital hyperinsulinism showed no statistically significant benefit (45% reduction in hypoglycemia vs. 40% on placebo), dashing hopes for the drug’s approval ([5]). Because XOMA holds a substantial royalty interest in RZ358 – entitling it to high-single-digit to mid-teens percentage royalties on future sales under a 2017 license deal ([6]) – the trial failure wiped out a potential major revenue stream. XOMA’s stock collapse mirrored Rezolute’s own 88% nosedive on the news ([5]), underscoring how concentrated pipeline risk can swiftly erode value in XOMA’s business model. Investors are now grappling with the implications: XOMA loses a prospective royalty that analysts once projected could yield tens of millions annually if RZ358 succeeded ([6]). This shock has refocused attention on XOMA’s fundamentals – its dividend policy, leverage, valuation, and the other assets underpinning its future growth – as the market reassesses the company’s risk/reward profile.
Dividend Policy & Cash Flows
Common Stock: XOMA does not pay a dividend on its common shares, as it prioritizes reinvesting cash flows into acquiring new royalty rights and supporting partner programs. The company’s growth-oriented strategy means common shareholders have so far seen returns through stock appreciation (and volatility) rather than cash payouts. Indeed, XOMA’s recent earnings have been negative or modest due to high upfront costs, so a regular common dividend has not been initiated ([1]). In 2024, XOMA achieved a milestone of generating positive operating cash flow – management noted that cash receipts exceeded base operating expenses for the year ([3]). This essentially means the company’s royalty and milestone inflows now cover its core overhead, a proxy for funds available for distribution. However, after servicing debt interest and preferred dividends (discussed below), no AFFO/FFO remains for common shareholders. In other words, XOMA’s adjusted funds from operations are currently fully absorbed by fixed charges and reinvestment, leaving a 0% common yield. Management’s focus is on using any surplus cash to acquire additional royalty assets and occasionally repurchase stock, rather than initiate a common dividend ([2]) ([2]). Investors thus shouldn’t expect a common-stock yield until XOMA’s royalty portfolio matures significantly and produces sustained free cash flow beyond its obligations.
Preferred Stock: Notably, XOMA does pay dividends on its preferred shares. The company has two series of cumulative perpetual preferred stock – an 8.625% Series A (NASDAQ: XOMAP) and an 8.375% Series B (NASDAQ: XOMAO) – issued to raise capital for acquisitions ([7]) ([8]). These preferreds have a $25 liquidation preference and pay quarterly cash dividends of ~$0.5234 per depositary share (equivalent to ~$2.09 annually, an 8.4–8.6% yield) ([7]) ([8]). XOMA has consistently declared and paid these preferred dividends every quarter, reflecting its commitment to fixed-income investors ([4]) ([9]). In mid-2024, for example, XOMA paid a total of $1.4 million in cash dividends on its Series A and B preferreds ([4]). The preferred dividends are cumulative, meaning any missed payments would accrue – but so far XOMA’s cash flows have been sufficient to meet them. These high-yield preferreds represent a significant cost of capital (see Coverage section) but also provide a cushion: common shareholders cannot receive any dividend until the preferred dividends are fully paid. In summary, XOMA’s dividend policy has been to reward preferred stockholders with an ample fixed yield, while common stockholders are asked to be patient for future upside rather than near-term income.
Leverage & Debt Maturities
XOMA employs substantial leverage to finance its royalty acquisitions, using both debt and preferred equity. Its most prominent debt is a royalty-backed credit facility with Blue Owl Capital, which gave XOMA a large influx of cash without diluting common shareholders. In December 2023, XOMA entered a non-recourse loan agreement for up to $140 million with funds managed by Blue Owl’s credit arm ([2]) ([10]). The company immediately drew $130 million in principal and can draw an additional $10 million if certain royalty performance thresholds are met by 2026 ([10]). Interest on the loan is fixed at 9.875% per annum, with semi-annual payments ([10]). The loan is secured and repaid by royalties from Vabysmo (faricimab), a blockbuster eye drug for which XOMA had acquired royalty rights in 2021 ([2]) ([10]). Essentially, XOMA monetized its Vabysmo royalty stream by pledging it to Blue Owl: XOMA must use the Vabysmo royalties (and other funds if needed) to pay the ~$12.8 million annual interest, and eventually repay principal over a lengthy 15-year term ([10]). The loan is non-recourse to XOMA’s other assets, meaning if royalties underperform, Blue Owl can only claim the Vabysmo-linked payments – not XOMA’s entire portfolio. This structure protects XOMA’s core business, but failure to service the interest could forfeit a valuable income stream. XOMA also granted Blue Owl warrants for 120,000 common shares (strike prices $35–$50) as an equity kicker for the deal ([10]). The Blue Owl debt has no near-term maturity (final maturity around 15 years out, with prepayment allowed anytime) ([10]), so XOMA faces no imminent principal repayment cliff. However, the 9.875% interest is a hefty fixed burden through 2038 unless prepaid.
7 Secrets to Start Investing in Gold & Silver
- Which coins are IRA-approved
- How to protect against inflation
- Fast checklist to buy your first coins
Beyond the Blue Owl loan, XOMA’s capital structure includes the two series of preferred stock discussed earlier, totaling roughly $60–70 million in face value (each preferred depositary share represents 1/1000th of an actual preferred share) ([7]) ([8]). These preferreds are perpetual (no maturity date) but callable at XOMA’s option after a certain date (typically ~5 years from issuance). Series A was issued in late 2022, and Series B in 2023, so their first call dates will likely be in 2027 and 2028, respectively (at $25 per share) – assuming XOMA wishes to refinance or redeem them. Until then, the company must pay the high 8.4–8.6% coupons indefinitely.
It’s worth noting XOMA’s leverage ramped up significantly in 2023–2024. The Blue Owl financing alone added $130 million debt, and the preferred issuances added another ~$65 million of quasi-debt capital. Meanwhile, XOMA has also executed creative M&A: for example, it acquired Kinnate Biopharma in 2024 and LAVA Therapeutics in 2025, transactions structured with contingent value rights (CVRs) that limit cash outlay but share future upside with the acquired companies’ shareholders ([11]) ([12]). In the Kinnate deal, XOMA actually gained cash – Kinnate had so much cash on hand that after paying Kinnate shareholders and spinning out its pipeline, XOMA’s balance sheet netted an extra $9.5 million ([13]). XOMA then sold Kinnate’s R&D assets to other parties for up to $270 million in milestones plus royalties, of which 85% will go to the CVR holders (former Kinnate investors) and 15% will accrue to XOMA ([11]) ([11]). A similar approach was used with LAVA Therapeutics in late 2025 – XOMA paid ~$1.04 per share in cash to LAVA’s holders and issued a CVR, thereby acquiring rights to LAVA’s two partnered bispecific antibody programs (with J&J and Pfizer) without a large upfront cost ([12]) ([12]). These deals illustrate XOMA’s “asset-light” acquisition strategy: leverage other companies’ cash and partnerships, in exchange for sharing future royalties via CVRs. While this minimizes immediate debt financing needs, it means XOMA’s stake in any one acquired pipeline is partial (e.g. 15% of Kinnate assets’ future milestones) and the outcomes won’t be known for years. Therefore, debt and preferred stock remain XOMA’s primary fixed obligations, with no significant maturities until at least 2027 (preferred calls) and effectively 2038 (Blue Owl loan final due date). The challenge is carrying the cost of this leverage in the interim.
Coverage and Fixed-Charge Coverage
XOMA’s interest and preferred dividend obligations are substantial, raising questions about coverage ratios. The Blue Owl loan’s interest runs about $3.2 million per quarter ([14]), and quarterly preferred dividends add roughly $1.4 million ([4]) – together that’s ~$4.6 million in fixed charges every quarter, or ~$18–19 million per year. For comparison, in the third quarter of 2024 XOMA’s total revenue was only $7.2 million ([14]), and even in Q3 2025 (prior to the Rezolute news) revenue was ~$9.3 million ([15]). This indicates that interest+preferred outflows consumed a majority of operating income. Indeed, in Q3 2024 interest expense alone ($3.5 M) was nearly half of total revenue ([14]) ([14]). Over the first nine months of 2024, XOMA received $42.3 million in cash (royalties and milestones) ([14]), which covered its cash operating expenses and fixed charges with only a thin cushion. After paying ~$10.4 million of interest (3 quarters) and ~$4.2 million of preferred dividends, XOMA roughly broke even on an operating cash basis. Coverage ratios are therefore modest: by one measure, XOMA has roughly 2.8× coverage of its fixed charges by cash receipts (annualized ~$52 M cash inflow vs. ~$18.6 M outflow). However, that relies on continued milestone inflows – which are uneven by nature. Stripping out one-time milestone payments, recurring royalties from marketed products were closer to ~$20–25 million in 2024 (primarily from Vabysmo and other newly launched drugs) ([4]) ([4]). Against that baseline, the fixed charges would exceed annual core royalty revenue, meaning XOMA is not yet self-sufficient without milestones or new deals.
Start collecting royalty checks before the first national payout.
Step 1
Learn the exact royalty play paying monthly checks
Step 2
Start with as little as $50 — get paid next month
Step 3
Position yourself before Wall Street moves in
Positively, management asserts that the “anchor” royalties from marketed drugs will be enough to sustain a base level of positive cash flow ([3]). Key approved products contributing recurring royalties include Roche’s Vabysmo (ophthalmology), Day One’s OJEMDA (pediatric brain tumor therapy), and Zevra’s MIPLYFFA (arimoclomol for Niemann-Pick disease) ([3]). These three are expected to drive near-term growth and help cover overhead and interest. In fact, XOMA stated in April 2025 that it has “line of sight on sustainable positive cashflows [from] existing commercial royalty portfolio alone”, naming Vabysmo, OJEMDA, and MIPLYFFA as the anchors ([3]). The coverage challenge is that Vabysmo – likely the largest royalty – is currently redirected to service the Blue Owl loan (the royalty proceeds are used to pay interest and principal). XOMA still counts the revenue, but effectively it doesn’t retain that cash until the debt is repaid. Thus, investors should monitor interest coverage in terms of EBITDA or cash flow. As of Q3 2024, XOMA’s interest coverage ratio (EBITDA/interest) was weak – the company actually recorded a net loss that quarter despite royalty growth ([15]) ([15]). Looking forward, successful milestones from late-stage assets will be critical to bolster coverage. If more partnered trials fail (like Rezolute’s did), XOMA may have to lean on its cash reserves (about $147 M as of Q3 2024) ([14]) to keep servicing fixed obligations and funding new deals. In summary, XOMA’s fixed-charge coverage is currently thin but manageable, contingent on its royalty portfolio ramping up. The company has avoided default risk thanks to a large cash buffer and non-recourse debt structure, but until royalty revenues materially increase, the margin of safety on coverage remains narrow.
Valuation and Comparables
Valuing XOMA is challenging using traditional metrics, because the company is not yet consistently profitable and its assets are largely intangible royalty rights. XOMA’s earnings per share have been negative or minimal (Q3 2025 EPS was –$0.35) ([15]), so P/E ratios are not meaningful. Similarly, price-to-sales or price-to-book metrics don’t fully capture the embedded value of future milestone payments that may never appear on the balance sheet. As one analysis noted, XOMA lacks conventional valuation metrics like P/E or PEG, and even P/B or P/S appear odd due to the company’s atypical financial profile ([1]). Instead, XOMA trades on the anticipated value of its royalty portfolio. At a stock price around $26 after the recent drop, XOMA’s market capitalization is roughly $250–300 million ([1]). Backing out the substantial cash on hand (~$140 M) ([14]) and considering $130 M in debt, the enterprise value is in the low $200 millions. Investors are essentially pricing XOMA’s diverse pipeline (120+ assets) at a few hundred million dollars – a figure that could be justified by just a couple of successful drugs, but which could also be too high if many projects underperform.
Comparable companies: The closest peer is probably Royalty Pharma plc (NASDAQ: RPRX), a much larger royalty aggregator. Royalty Pharma generates over $2 billion in annual royalty revenues and pays a dividend, trading at roughly 12× forward earnings and a ~2.5% dividend yield in recent years. By contrast, XOMA is in an earlier stage of the model: its revenues over the last 12 months were only around $30 million and heavily augmented by one-time milestones ([4]). Royalty Pharma’s portfolio is weighted to already-marketed drugs, whereas XOMA’s valuation reflects significant pipeline optionality. In effect, XOMA behaves like a hybrid of a biotech venture fund and a royalty investment vehicle. Traditional REIT-like metrics (FFO/AFFO) aren’t formally reported by XOMA, but if we approximate “adjusted cash earnings,” the company might have generated only a few million dollars of true free cash in 2024 after expenses – implying a very high multiple on current cash flows.
Congratulations — Your seat is almost reserved!
Get 6 ten-bagger ideas + alerts from Gerardo. Instant access when you join.
Analysts’ view: Wall Street analysts have valued XOMA by sum-of-the-parts, modeling the risk-adjusted NPVs of key royalty assets. Before the Rezolute trial failure, analyst price targets suggested significant upside – e.g. SVB Leerink (now part of Piper Sandler) had upgraded XOMA’s target to $58/share in November 2025, on an “Outperform” rating, citing undervaluation of its royalty streams ([16]). However, after RZ358’s failure, Leerink slashed its target, removing the RZ358 royalty from its model, and reportedly reset the target around $26 (essentially where the stock fell) ([17]). According to a report from Investing.com, the consensus of analysts still remains Bullish – with strong-buy ratings and price targets ranging from $50 up to $100 (likely assuming success of other pipeline assets) ([17]). This wide range highlights the speculative nature of XOMA’s valuation: a single drug’s outcome can swing the perceived value by hundreds of millions. For instance, RZ358 was expected to be one of XOMA’s largest future royalty streams ([6]) ([6]); with that gone, the market is now looking to what’s next in the pipeline to justify the stock’s price. In sum, XOMA’s valuation is primarily story-driven and catalyst-driven. It is not anchored by earnings or yield, but by the potential upside of its royalty portfolio. This makes comps difficult – investors must essentially discount XOMA’s portfolio of milestones/royalties. At the current price near $25, the market appears to be valuing the remaining pipeline more cautiously after the recent setback. XOMA’s own book value is bolstered by cash (over $10/share in cash) ([14]), so downside may be buffered by that and its existing commercial royalties. Upside, on the other hand, depends on delivering positive trial results and product launches in 2025–2026 from its late-stage assets.
Key Risks
Pipeline Failures: The greatest risk to XOMA is that its partnered drug candidates fail in clinical trials or struggle to gain approval. The Rezolute fiasco is a vivid example – a Phase 3 failure can instantly obliterate a significant anticipated revenue source ([5]). XOMA has 11 assets in Phase 3 development as of early 2025 ([3]) ([3]), and not all will succeed. The portfolio’s value is highly sensitive to these binary outcomes. For instance, another upcoming catalyst is seralutinib (Gossamer Bio/Chiesi’s drug for pulmonary arterial hypertension) – if its Phase 3 readout in 2025 is negative, XOMA would lose a potential royalty that management counted among key mid-term drivers ([3]). Failures in other Phase 3 assets (or even Phase 2) can lead to impairment charges and lost future income, as seen when XOMA had to write down royalties after partners halted programs (e.g. Bioasis in 2023, Aronora in 2024) ([4]) ([4]). In summary, clinical and regulatory risk is the number-one issue: XOMA is essentially as risky as the biotech pipeline it owns rights to, albeit diversified across many shots on goal.
Concentration of Revenue: Despite a big portfolio, a few assets dominate XOMA’s near-term economics. In 2024, two commercial products (likely Vabysmo and one other) accounted for $4.9 M of income in a single quarter ([4]) – a large share of total revenue. Vabysmo in particular is critical: it is a high-selling drug (for retinal disease) and XOMA’s loan is secured by its royalties ([2]) ([10]). If Vabysmo’s sales disappoint (due to competition like Regeneron’s Eylea or new treatments), or if any issue arises with that royalty contract, XOMA’s cash flow and debt repayment plans could be impacted. Similarly, OJEMDA and MIPLYFFA were just approved in 2023–24 and are expected to fuel growth ([3]). Any commercial setbacks for these small-market drugs (e.g. slow uptake or reimbursement hurdles) would hurt XOMA’s revenue forecasts. Geographic and partner concentration also matter: XOMA’s royalties often depend on a single partner’s success (e.g. Roche for Vabysmo, Day One for OJEMDA). If those partners face operational or financial difficulties, milestone payments might be delayed or royalties unpaid.
Financial Leverage: XOMA’s aggressive use of debt and preferred stock amplifies risk. The company has a high fixed-cost burden (nearly $19 M/year in interest + preferred dividends) that must be met regardless of whether milestone payments come in. While XOMA’s current cash reserve is large, continual shortfalls could eventually force the company to raise additional capital. If royalty revenues fall short, XOMA might need to issue new equity or debt to cover obligations – potentially diluting shareholders or straining the balance sheet. The Blue Owl loan’s terms, for example, require interest payments even if Vabysmo royalties fluctuate, and prolonged underperformance could trigger covenants or see XOMA’s remaining Vabysmo royalty diverted entirely to the lender. The preferred stock is cumulative; failure to pay those dividends would likely bar XOMA from raising common dividends or other junior capital, and could harm its market reputation. Overall, financial risk is significant for a company of XOMA’s size carrying >$130 M debt and ~$65 M in preferred equity.
Market Volatility & Liquidity: XOMA’s stock itself is volatile. In the past 52 weeks it ranged from about $18 to $40 per share ([18]), at times moving sharply on little news. This volatility reflects the speculative nature of the business – small changes in perceived pipeline value or rumors can swing the market cap. For investors, this means risk of sudden drawdowns (as seen with the 22% single-day drop ([18])) and potentially low liquidity on some days. There’s also event risk around earnings or partner announcements; for example, a delay in an FDA decision or a partner’s financing news can move XOMA disproportionately.
Partner Execution & Credit Risk: XOMA relies on its partners to advance clinical trials, obtain regulatory approvals, and successfully commercialize products. These are mostly small to mid-size biotech firms (Rezolute, Day One, Zevra, etc.) rather than large pharmas – although some assets are partnered with big players like Novartis, Takeda, or Johnson & Johnson via earlier deals ([14]) ([14]). Smaller partners carry higher credit risk and operational risk. For instance, if a partner runs out of funding, a trial might stall (XOMA doesn’t typically fund trials itself). In 2020, XOMA noted relief when Rezolute raised capital from investors, as it triggered a payment to XOMA and helped ensure RZ358 development continued ([19]). Conversely, if a partner like Rezolute becomes financially distressed after a trial failure, XOMA might recover little value (Rezolute’s stock collapse leaves XOMA’s equity stake in Rezolute – gained as part of the original license – almost worthless ([5])). Even approved products carry risk if partners cannot market them effectively or decide to discontinue a product. In short, XOMA has minimal control over the fate of its underlying assets beyond negotiating the initial license/royalty terms.
Regulatory and Legal Risks: As a royalty holder, XOMA generally isn’t liable for drug safety or manufacturing issues, but it’s still exposed to regulatory outcomes. If a partner’s product faces unexpected FDA hurdles or safety concerns, XOMA’s royalty can vanish. Legal disputes could also arise – e.g. if a partner tries to renegotiate or if patents are challenged. Additionally, XOMA must comply with complex revenue recognition and tax rules for its royalty monetizations; any misstep in accounting or disclosures (especially given the novel CVR structures and non-standard deals) could pose a risk.
Red Flags & Notable Concerns
Beyond the general risks, a few red flags stand out in XOMA’s recent trajectory:
– Reliance on One-Time Revenues: XOMA’s earnings have been heavily influenced by lumpy milestone payments and accounting gains. For example, in Q2 2024 XOMA recorded a $19.3 million one-time gain from its bargain purchase of Kinnate ([4]), and that quarter’s $11.1 M revenue included a $5.0 M milestone from Rezolute and a $0.5 M milestone from an FDA approval ([4]). Such non-recurring items flattered results – in contrast, Q3 2024 revenue was only $7.2 M without big milestones ([14]). The volatility in quarterly earnings (e.g. a big beat one quarter, a big miss the next) ([15]) ([15]) suggests the core royalty business is still not generating steady, predictable income. This raises a flag that true underlying cash flow is hard to assess and may not yet justify the stock’s valuation absent continued deals.
– High Cost of Capital: The fact that XOMA pays ~9–10% interest on debt and ~8.5% on preferred equity ([10]) ([7]) signals that traditional financing sources view XOMA as a high-risk borrower. This expensive capital structure means management felt these assets were worth it – but it also puts pressure on XOMA to achieve a high return on its investments. If new royalty acquisitions don’t yield >10% returns, XOMA could destroy shareholder value by effectively paying out more in interest/dividends than it earns on the assets. The outsized yields on XOMA’s preferreds, for instance, are far above typical corporate bond rates, indicating investors demand a big risk premium. It’s a red flag whenever a company must finance itself at nearly double-digit rates; it suggests underlying business risk that debt investors see.
– Complex Acquisition Structures: XOMA’s use of CVRs and reverse-merger-like deals (Kinnate, LAVA) makes its accounting and corporate structure more complicated ([11]) ([11]). While these deals can be clever (netting XOMA cash and pipeline optionality), they involve multiple moving parts – asset sales, sharing proceeds with CVR holders, integration of acquired entities – which could create execution risk or unexpected liabilities. For example, XOMA must manage the obligations to CVR holders from Kinnate’s deal through 2029, handing over 85% of any relevant income ([11]). If not managed properly, such obligations could cause confusion about how much value XOMA actually keeps. Investors might worry that management is stretching into quasi-liquidation arbitrage strategies as opposed to pure royalties, which may distract from core operations.
– Insider Trading and Ownership: Data shows relatively modest insider trading activity – in the past six months insiders made 3 sales and only 1 purchase of XOMA stock ([20]). While not egregious, insider sales (especially if by executives) can be a yellow flag, potentially signaling insiders taking profits or lacking confidence at certain price levels. On the positive side, some specialized biotech investors (e.g. BVF Partners) have been involved in XOMA historically. Still, the stock is closely held enough that any insider moves are watched. There have been no known large insider buying sprees despite price dips, which could imply management believes the best use of cash is doing more deals (not buying their own stock beyond small buybacks).
– Volatility and Investor Sentiment: XOMA’s sharp price swings and wide analyst target range (from $26 up to $100) ([17]) point to a potential disconnect between management’s narrative and market acceptance. For instance, even before the Rezolute news, XOMA’s stock hit a 52-week low of ~$19 in March 2025 ([21]) after general market shifts, suggesting investor sentiment can sour quickly on this name. Any company that loses a quarter of its value in a day (as happened in the recent plunge ([18])) inevitably attracts scrutiny. It raises the question of whether risk management and communication from the company are adequate. Did XOMA properly telegraph the risks around Rezolute’s trial? Moving forward, investors might be skeptical of management’s projections (e.g. “sustainable positive cashflow” claims ([3])), given how one event upended the outlook. Maintaining credibility will be crucial – this is a soft factor but critical in a venture-like entity.
– No Common Shareholder Returns Yet: While not exactly a red flag, it’s a point of concern that after years of operations as a royalty aggregator, XOMA’s common shareholders have not seen dividends or buybacks of significant magnitude. The company did initiate a small stock repurchase program with some of the Blue Owl loan proceeds, but repurchases have been minimal (~$13k recorded in a quarter, which may have just been to offset employee stock grants) ([14]). If the strategy is truly working, one might expect by now some tangible return. The lack thereof could imply that XOMA must continually reinvest just to keep the growth engine going, with little excess yet. Common stockholders are effectively last in line behind debt and preferred – a structure that can be risky if things don’t go as planned.
In aggregate, these concerns do not necessarily mean XOMA is unsound, but they underscore that this is a high-risk, high-reward scenario. Investors should keep an eye on how management addresses the fixed-cost burden, whether they temper complexity and risk, and if they eventually deliver stable cash yields to shareholders.
Open Questions & Outlook
The steep stock drop raises several open questions about XOMA’s path forward:
– How Will XOMA Fill the RZ358 Gap? – With the Rezolute royalty essentially gone, what asset will step up to drive growth? XOMA highlighted other late-phase programs (e.g. Gossamer’s seralutinib for PAH, Takeda’s mezagitamab for ITP, J&J’s cetrelimab in bladder cancer) due for data in 2025–26 ([3]) ([14]). Investors will be watching these closely. A success in one could restore confidence, but further failures would compound the damage. XOMA may also respond by acquiring new royalty assets to replenish its pipeline – any new deals or partnerships announced in coming months will be telling.
– Can the Royalty Portfolio Reach Self-Sustainability? – XOMA’s management believes the existing royalty base can cover operating costs and then some ([3]). As more products like Sildenafil Cream 3.6% (Daré’s women’s health product) come online (anticipated as XOMA’s 7th revenue-generating asset by Q4 2025) ([3]), will recurring cash flows finally exceed the hefty interest and preferred payouts with a comfortable margin? This will determine if XOMA can eventually pay something to common shareholders or reduce debt. In the meantime, cash burn vs. cash earnings will be a key metric to track each quarter.
– Will XOMA Alter Its Financial Strategy? – The company has leveraged up during a low-interest boom in biotech royalties. Now with higher rates and a stressed stock price, does XOMA consider deleveraging or pausing acquisitions? It could choose to pay down some of the Blue Owl debt early (the loan is prepayable) to save interest, or even consider buying back some preferred shares if they trade at a discount. On the other hand, management might double down on opportunistic acquisitions given low biotech valuations ([3]) ([3]). How they strike this balance of risk vs. growth is an open question.
– Is a Joint Venture or Sale Possible? – XOMA’s stock weakness and relatively small size could make it a takeover target or a candidate for a larger royalty fund partnership. For instance, might a bigger player like Royalty Pharma or an institutional investor attempt to acquire XOMA (or a stake in its portfolio) now that its market cap is pared down? Alternatively, XOMA could partner on specific assets to offload risk. No such moves have been indicated yet, but strategic alternatives could surface if the stock remains depressed.
– When Do Common Shareholders See Returns? – Ultimately, the investment thesis for XOMA will hinge on whether it can transition from reinvesting mode to cash-generating mode. Management’s long-term goal likely includes paying dividends or executing more significant buybacks once cash flows stabilize. Given the current trajectory, is that 2 years away? Five years? Or will XOMA simply keep scaling up (using all cash for new deals) without a payout until it’s much larger? Clarity on this in upcoming investor communications or the next shareholder letter would help set expectations.
– Are There Hidden Risks? – The Rezolute outcome showed a known risk; investors should also probe for any less obvious liabilities. For example, are there any minimum payment guarantees in XOMA’s deals that could obligate it to pay out if milestones aren’t met (unlikely, but worth checking SEC filings)? How about the Blue Owl covenants – could a drop in XOMA’s credit rating or a material adverse event trigger any loan issues? So far, none are publicly reported ([10]) ([10]), but it’s a point to monitor as debt investors often have protections. Another subtle risk: tax treatment of royalty revenues can be complex – any changes in tax law or adverse IRS rulings on XOMA’s non-recurring gains could impact net cash.
Going forward, investors in XOMA will need to closely follow partner news flow – essentially tracking a mini-portfolio of biotech trials and launches. The royalty aggregator model can yield big rewards if even a few assets hit (the upside of a successful Phase 3 could be a multi-fold increase in royalties and stock value), but it also means XOMA’s fate can swing quickly on scientific outcomes outside its control. After the recent plunge, XOMA’s stock is in “show me” territory: management must execute flawlessly – maintaining financial discipline and scoring a couple of pipeline wins – to rebuild trust. For now, the stock’s decline is a cautionary tale about the risks inherent in royalty stocks, even as the long-term promise of XOMA’s model remains if its portfolio delivers results ([5]) ([3]). The next year will be pivotal in determining whether this drop was a temporary setback or a sign of deeper challenges ahead for XOMA Royalty Corporation.
Sources
- https://directorstalkinterviews.com/xoma-royalty-corporation-xoma-stock-analysis-unpacking-a-152-potential-upside/4121210099
- https://globenewswire.com/news-release/2023/12/19/2798450/7281/en/XOMA-Raises-up-to-140-Million-in-Non-Dilutive-Non-Recourse-Financing-from-Funds-Managed-by-Blue-Owl-Capital-Backed-by-VABYSMO-Royalties.html
- https://xoma.com/2025-letter-to-stockholders/
- https://investors.xoma.com/news-events/press-releases/detail/459/xoma-royalty-reports-second-quarter-2024-financial-results
- https://ainvest.com/news/xoma-royalty-plummets-22-87-fueling-selloff-2512/
- https://mx.advfn.com/bolsa-de-valores/NASDAQ/RZLT/cotizacion
- https://stocktitan.net/news/XOMA/xoma-royalty-declares-quarterly-preferred-stock-xb49lmqf8nt1.html
- https://stocktitan.net/news/XOMAO/xoma-royalty-declares-quarterly-preferred-stock-xb49lmqf8nt1.html
- https://investors.xoma.com/news-events/press-releases/detail/461/xoma-royalty-declares-quarterly-preferred-stock-dividends
- https://investors.xoma.com/news-events/press-releases/detail/441/xoma-raises-up-to-140-million-in-non-dilutive
- https://investors.xoma.com/news-events/press-releases/detail/472/xoma-royalty-completes-sale-of-kinnate-pipeline-assets
- https://stocktitan.net/news/XOMA/xoma-royalty-announces-closing-of-transactions-to-acquire-lava-nabujoyxo7u1.html
- https://globenewswire.com/news-release/2024/02/16/2830729/7281/en/XOMA-Enters-into-Agreement-to-Acquire-Kinnate-Biopharma-for-Between-2-3352-and-2-5879-in-Cash-Per-Share-Plus-a-Contingent-Value-Right.html
- https://investors.xoma.com/news-events/press-releases/detail/464/xoma-royalty-reports-third-quarter-2024-financial
- https://nasdaq.com/articles/xoma-royalty-xoma-reports-q3-loss-lags-revenue-estimates
- https://th.investing.com/news/analyst-ratings/article-93CH-513415
- https://vn.investing.com/news/analyst-ratings/leerink-partners-ha-muc-tieu-gia-co-phieu-xoma-sau-that-bai-thu-nghiem-rz358-93CH-2493019
- https://ainvest.com/news/xoma-royalty-plummets-21-87-sudden-freefall-2512/
- https://investors.xoma.com/news-events/press-releases/detail/380/xoma-highlights-recent-royalty-asset-portfolio-developments
- https://quiverquant.com/news/%24XOMA%2Bstock%2Bis%2Bdown%2B23%25%2Btoday.%2BHere%27s%2Bwhat%2Bwe%2Bsee%2Bin%2Bour%2Bdata.
- https://investing.com/news/company-news/xoma-stock-touches-52week-low-at-2107-amid-market-shifts-93CH-3903593
For informational purposes only; not investment advice.
